What it does
CJC-1295 is a synthetic analog of GHRH (1-29). The 'with DAC' version includes a Drug Affinity Complex linker that binds serum albumin, extending half-life to several days. The 'no DAC' version (also called Modified GRF 1-29 or MOD-GRF) lacks that linker and has a half-life of ~30 minutes — closer to native GHRH and the standard pairing for self-experimenters who want pulsatile release with a GHRP like ipamorelin. Human pharmacokinetic data exist; outcome data on body composition or healthspan is much thinner.
Dose
- Starting
- 30 mcg · see notes
- Common
- 140 mcg · see notes
- Upper
- 250 mcg · see notes
- When
- BedtimeAligns with the natural GH pulse during early-night slow-wave sleep. CRITICAL: empty stomach — wait 3+ hours after the last meal. Food blunts the GH response sharply.
- How long
- 6 months on / 2 months off
- Site
- subcutaneous
- Food
- fasted
Need exact volumes? Open the peptide calculator →
⚠ Caution
- Active malignancy (relative)
- Pregnancy and breastfeeding
- Pituitary or hypothalamic disease — confirm with provider before use
- Severe insulin resistance or uncontrolled diabetes
- Hypersensitivity to GHRH analogs
Medications & conditions
- CJC-1295 with corticosteroid — blunted GH responseUser is taking a corticosteroid. Chronic high-dose glucocorticoid use suppresses hypothalamic GHRH secretion and reduces pituitary sensitivity, meaningfully blunting the GH-releasing effect of CJC-1295. Benefit of the peptide may be substantially reduced until steroid dose is tapered.
Will it work for me?
Establish a baseline (2–3 readings over 1–2 weeks before starting), then track at consistent intervals.
- Tier 1 — Human RCTIGF-1↑· by 8 weeks; stay within age-adjusted range — do not chase supraphysiologicTarget 30–80% rise from baseline within the age-adjusted reference range. IGFBP-3 as confirmatory.
- Tier 2 — Human observationalLean mass % via DEXA↑· 12 weeks+
- Tier 3 — Animal / in vitroSleep quality (PSQI)↓· 2–4 weeksLower PSQI = better sleep.
Often stacked with
- Ipamorelin — CJC-1295 (GHRH analog) primes somatotroph GHRH receptors; Ipamorelin (ghrelin-receptor agonist) pulls the GH-release trigger — dual pathway produces a larger, cleaner GH pulse than either alone.
- IGF-1 LR3 — CJC-1295 raises endogenous GH (upstream); IGF-1 LR3 provides direct downstream IGF-1R agonism with extended half-life — serial pathway amplification, but timing and monitoring requirements differ.
Your stack
Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.
Add to my stack